ACADIA Pharmaceuticals Inc. vs Payoneer Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× Payoneer Global Inc's market cap. Which is the better fit depends on your goals.
| ACAD | PAYO | |
|---|---|---|
Market Cap | $5.07B | $2.40B |
Sector | Health | Technology |
52-Week High | $29.41 | $7.17 |
52-Week Low | $20.06 | $4.27 |
Enterprise Value | $4.19B | $2.14B |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →